BTG plc (LON:BTG) issued its quarterly earnings results on Tuesday. The company reported GBX 21 ($0.28) earnings per share for the quarter, meeting the consensus estimate of GBX 21 ($0.28), Bloomberg Earnings reports. BTG plc had a net margin of 7.26% and a return on equity of 4.33%. The business had revenue of GBX 3,413 billion for the quarter.
Shares of BTG plc (BTG) opened at GBX 702 ($9.23) on Tuesday. BTG plc has a 12 month low of GBX 528.36 ($6.95) and a 12 month high of GBX 779 ($10.25).
ILLEGAL ACTIVITY NOTICE: “BTG plc (BTG) Issues Quarterly Earnings Results” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/14/btg-plc-btg-issues-quarterly-earnings-results.html.
BTG has been the topic of several analyst reports. Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 775 ($10.19) price target on shares of BTG plc in a report on Friday, October 6th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 900 ($11.84) price target on shares of BTG plc in a report on Wednesday, October 18th. Peel Hunt reaffirmed a “hold” rating and set a GBX 680 ($8.94) price target on shares of BTG plc in a report on Tuesday, October 31st. J P Morgan Chase & Co reissued a “neutral” rating on shares of BTG plc in a report on Monday, September 18th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a GBX 800 ($10.52) target price on shares of BTG plc in a report on Wednesday, August 30th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. BTG plc has a consensus rating of “Buy” and a consensus target price of GBX 779.13 ($10.25).
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.